According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...

Crispr stock reversed lower Monday, while Intellia stock surged, on promising updates for their gene-editing efforts.

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...

CRISPR Therapeutics (CRSP) shares have seen notable movement over the past month, with the stock down about 25%. Investors are watching closely to see how recent developments may shape future ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

Meanwhile, ARK sold 15,362 shares of Roku Inc (NASDAQ:ROKU) through its ARKK ETF, totaling $1,668,774. This marks a continuation of ARK’s recent trend of reducing its holdings in the streaming ...

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...

The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...